Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00072449 · FLOW

Participant flow

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma · Source last updated 2013-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
    id
    FG000
    title
    Rituximab Monotherapy
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
    id
    FG000
    title
    Rituximab Monotherapy
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice